Univercells Technologies introduces new upstream platform for virus manufacturing
The NevoLine Upstream platform has been designed to address the needs of gene therapy and vaccine innovators and CDMOs for robust and cost-effective upstream viral vectors manufacturing.
Univercells Technologies has introduced a new platform in the NevoLine biomanufacturing product family, the NevoLine Upstream platform.
This high-performance, low-footprint upstream manufacturing platform is suitable for multiple viral applications to support the booming gene therapy market and offers a cost-effective tool for rapid response to emerging infectious diseases.
The innovative design aims to revolutionize upstream processing by intensifying and chaining all unit operations from inoculation to midstream processing to deliver a concentrated, clarified bulk.
With the NevoLine Upstream platform, commercial-scale upstream production is possible in a 3-m² module, a 3-fold reduction in equipment footprint compared with conventional technologies.
The platform has been designed to address the needs of gene therapy and vaccine innovators and CDMOs for robust and cost-effective upstream viral vectors manufacturing.
It builds on the successful proof of concept with the first NevoLine biomanufacturing platform, which was specially designed for affordable production of a trivalent Sabin Inactivated Polio Vaccine (sIPV).
In application, the original NevoLine sIPV platform demonstrated how the chaining of unit operations could intensify processes for drastic footprint and cost reductions, with the ability to deliver more than 500,000 doses per batch below 0.30 EUR/dose, within a 10 m² equipment footprint.
The system accommodates all unit operations from inoculation to midstream processing and is suited for GMP, clinical and commercial manufacturing of vaccines, gene therapies and oncolytic viruses.
The automated platform offers a flexible solution for multiple viral applications by combining single-use assemblies in process-specific configurations. At the core of the platform is the scale-X nitro structured fixed-bed bioreactor, providing up to 600 m² of growth surface.
Mammalian cell culture and virus production can be combined with concentration and single or multi-step clarification for intensified and continuous processes that deliver high productivity with drastically reduced operational costs.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance